SHANGHAI – A transdermal pain patch being studied by Frontier Biotechnologies Inc., of Nanjing, China, has met its primary endpoints in a U.S. phase II trial of 146 patients with chronic lower back pain. The super-thin patch – only 200 micrometers thick – was designed to overcome safety issues common in prescription-strength painkillers for chronic pain.